CelLBxHealth plc (ANPCY) Research

Headquartered in Guildford, United Kingdom, and established in 1994, CelLBxHealth plc (formerly known as ANGLE plc until October 2025) is a medical diagnostics company dedicated to advancing cancer detection. The firm's reach extends globally, with operations in the UK, Europe, and North America. CelLBxHealth's product portfolio features innovative medical devices such as the Parsortix PC1 system, specifically engineered to isolate and collect intact circulating tumor cells (CTCs) from the blood of metastatic breast cancer patients for subsequent user-validated analysis. They also offer the Parsortix PR1 system for general CTC capture. Further enhancing their diagnostic capabilities are the Portrait+ CTC Staining kit, a ready-to-use laboratory tool providing high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs, alongside the CellKeep Slide for efficient CTC harvesting. In addition to its product line, the company provides comprehensive laboratory services, including CTC enrichment and liquid biopsy analysis. Their specialized assays encompass Portrait Flex, an immunofluorescence test for identifying epithelial, mesenchymal, and epithelial-to-mesenchymal transition (EMT) cells, as well as assessing DNA damage response. They also offer Portrait PD-L1 for evaluating CTCs and develop bespoke CTC assays. Strategic alliances are a key component of their development strategy, including a partnership with BioView Ltd to create a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. to leverage a pan-cancer next-generation sequencing (NGS) panel.

Open CelLBxHealth plc (ANPCY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.